-
Abstract Number: 2476
The Impact of Systemic Sclerosis Manifestations on Survival and Humanistic Burden: A Targeted Literature Review
-
Abstract Number: 2477
Quantifying Tissue Microstructural Changes in Scleroderma Skin Using a Novel, Point-of-care, High-frequency-ultrasound Instrument
-
Abstract Number: 2478
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
-
Abstract Number: 2479
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
-
Abstract Number: 2480
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
-
Abstract Number: 2481
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
-
Abstract Number: 2482
Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
-
Abstract Number: 2483
Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study
-
Abstract Number: 2484
Real-World Use of Avacopan for ANCA-Associated Vasculitis Beyond 52 Weeks
-
Abstract Number: 2485
Orbital Pseudotumor in Granulomatosis with Polyangiitis. Interim Analysis of Clinical Outcomes from a European Collaborative Observational Study
-
Abstract Number: 2486
Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
-
Abstract Number: 2487
Comparing Circulating Protein Profiles in Patients with Active Myeloperoxidase (MPO) vs Proteinase-3 (PR3) Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
-
Abstract Number: 2488
Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis
-
Abstract Number: 2489
Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting
-
Abstract Number: 2490
Longitudinal Kidney Function Trajectories in Patients Enrolled in the Plasma Exchange and Glucocorticoids in ANCA-Associated Vasculitis Trial
- « Previous Page
- 1
- …
- 165
- 166
- 167
- 168
- 169
- …
- 181
- Next Page »